


CLAIMS

What is claimed is:

1. A compound having the Formula I



5




wherein

10

R^1 is pyridyl, - CH_2 -pyridyl, substituted pyridyl, - CH_2 -substituted pyridyl,

phenyl, substituted phenyl,  ,  , or







each R^a and R^b are independently hydrogen or $\text{C}_1\text{-C}_6$ alkyl;




m is 0 to 4;

15

n is 0, 1, or 2;


R^2 is substituted phenyl, phenyl,  ,






5 pharmaceutically acceptable salt thereof.

2. A compound in accordance with Claim 1 wherein



3. A compound in accordance with Claim 1 wherein



10 4. A compound in accordance with Claim 1 wherein

R^1 is pyridyl, or $-CH_2$ -pyridyl.


5. A compound in accordance with Claim 1 wherein

R^1 is substituted phenyl or substituted pyridyl.

6. A compound in accordance with Claim 1 wherein
R² is substituted phenyl, or phenyl.






7. A compound having the Formula I

5




wherein

10 R¹ is pyridyl, substituted phenyl, phenyl



15



5 substituted phenyl, or a pharmaceutically acceptable salt thereof.

8. The compounds:

2-Benzylsulfanyl-*N*-(4-methoxy-benzyl)-*N*-(4-methoxy-phenyl)-benzamide;

10 *N*-(3,5-Di-tert-butyl-benzyl)-3,4-dimethoxy-*N*-phenyl-benzamide;
N-(3,5-Bis-trifluoromethyl-benzyl)-3,4-dimethoxy-*N*-phenyl-benzamide;

15 *N*-(3,5-Dibromo-benzyl)-3,4-dimethoxy-*N*-phenyl-benzamide;
3,4-Dimethoxy-*N*-(4-methoxy-benzyl)-*N*-phenyl-benzamide;
3,4-Dimethoxy-*N*-(3-methoxy-benzyl)-*N*-phenyl-benzamide;
N-(3,4-Dichloro-benzyl)-3,4-dimethoxy-*N*-phenyl-benzamide;
3,4-Dimethoxy-*N*-naphthalen-2-ylmethyl-*N*-phenyl-benzamide;
N-(4-tert-Butyl-benzyl)-3,4-dimethoxy-*N*-phenyl-benzamide; and
N-Biphenyl-2-ylmethyl-3,4-dimethoxy-*N*-phenyl-benzamide.

9. The compounds:

20 *N*-(3,4-Dichloro-benzyl)-*N*-(2-methoxy-phenyl)-benzamide;

N-(3,5-Di-tert-butyl-benzyl)-*N*-[4-(3-diethylamino-propyl)-phenyl]-benzamide;

5 *N*-(3,5-Bis-trifluoromethyl-benzyl)-*N*-[4-(3-diethylamino-propyl)-phenyl]-benzamide;

N-(3,5-Dibromo-benzyl)-*N*-[4-(3-diethylamino-propyl)-phenyl]-benzamide;

10 *N*-[4-(3-Diethylamino-propyl)-phenyl]-*N*-(4-methoxy-benzyl)-benzamide;

N-[4-(3-Diethylamino-propyl)-phenyl]-*N*-(3-methoxy-benzyl)-benzamide;

15 *N*-(3,4-Dichloro-benzyl)-*N*-[4-(3-diethylamino-propyl)-phenyl]-benzamide;

N-[4-(3-Diethylamino-propyl)-phenyl]-*N*-naphthalen-2-ylmethyl-benzamide;

N-Biphenyl-2-ylmethyl-*N*-[4-(3-diethylamino-propyl)-phenyl]-benzamide; and

 3-Methyl-thiophene-2-carboxylic acid (4-*ido*-phenyl)-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-ylmethyl)-amide.

10. The compounds:

20 *N*-(4-Methoxy-benzyl)-*N*-phenyl-benzamide;

N-(3-Methoxy-benzyl)-*N*-phenyl-benzamide;

 3,4,5-Trimethoxy-*N*-naphthalen-2-ylmethyl-*N*-quinolin-3-yl-benzamide;

25 *N*-(4-tert-Butyl-benzyl)-3,4,5-trimethoxy-*N*-quinolin-3-yl-benzamide;

N-Biphenyl-2-ylmethyl-3,4,5-trimethoxy-*N*-quinolin-3-yl-benzamide;

 3,4,5-Trimethoxy-*N*-(6-methoxy-pyridin-3-yl)-*N*-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-ylmethyl)-benzamide;

30 *N*-(3,5-Di-tert-butyl-benzyl)-3,4,5-trimethoxy-*N*-(6-methoxy-pyridin-3-yl)-benzamide;

N-(3,4-Dichloro-benzyl)-3,4,5-trimethoxy-*N*-(6-methoxy-pyridin-3-yl)-benzamide;

35 4-Isopropyl-*N*-pyridin-3-yl-*N*-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-ylmethyl)-benzamide; and

 4-Isopropyl-*N*-(3-methoxy-benzyl)-*N*-pyridin-3-yl-benzamide.

11. The compounds:

5 4-Isopropyl-*N*-naphthalen-2-ylmethyl-*N*-pyridin-3-yl-benzamide;
 'N-(4-tert-Butyl-benzyl)-4-isopropyl-*N*-pyridin-3-yl-benzamide;
 N-Biphenyl-2-ylmethyl-4-isopropyl-*N*-pyridin-3-yl-benzamide;
10 2-Ethoxy-*N*-pyridin-3-yl-*N*-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-ylmethyl)-benzamide;
 N-(3,5-Di-tert-butyl-benzyl)-2-ethoxy-*N*-pyridin-3-yl-benzamide;
 N-(3,5-Dibromo-benzyl)-2-ethoxy-*N*-pyridin-3-yl-benzamide;
 2-Ethoxy-*N*-(4-methoxy-benzyl)-*N*-pyridin-3-yl-benzamide;
15 2-Ethoxy-*N*-(3-methoxy-benzyl)-*N*-pyridin-3-yl-benzamide;
 N-(3,4-Dichloro-benzyl)-2-ethoxy-*N*-pyridin-3-yl-benzamide; and
 2-Ethoxy-*N*-naphthalen-2-ylmethyl-*N*-pyridin-3-yl-benzamide.

12. The compounds:

15 *N*-(4-tert-Butyl-benzyl)-2-ethoxy-*N*-pyridin-3-yl-benzamide;
 N-Biphenyl-2-ylmethyl-2-ethoxy-*N*-pyridin-3-yl-benzamide;
 N-(6-Butoxy-pyridin-3-yl)-2-diethylamino-*N*-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-ylmethyl)-acetamide;
 N-(6-Butoxy-pyridin-3-yl)-*N*-(4-tert-butyl-benzyl)-2-diethylamino-acetamide;
20 'N-Biphenyl-2-ylmethyl-*N*-(6-butoxy-pyridin-3-yl)-2-diethylamino-acetamide;
 N-(2-Methoxy-phenyl)-*N*-naphthalen-2-ylmethyl-benzamide;
 N-(4-Methoxy-benzyl)-*N*-(2-methoxy-phenyl)-benzamide;
 N-(3-Methoxy-benzyl)-*N*-(2-methoxy-phenyl)-benzamide;
25 *N*-Biphenyl-2-ylmethyl-*N*-(2-methoxy-phenyl)-benzamide; and
 N-[4-(3-Diethylamino-propyl)-phenyl]-*N*-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-ylmethyl)-benzamide.

13. The compounds:

30 *N*-Biphenyl-2-ylmethyl-2-ethoxy-*N*-(6-methoxy-pyridin-3-yl)-benzamide;
 N-Biphenyl-2-ylmethyl-2-methoxy-*N*-(6-methoxy-pyridin-3-yl)-benzamide;
 N-Biphenyl-2-ylmethyl-2-methoxy-*N*-pyridin-3-ylmethyl-benzamide;
35 Benzo[b]thiophene-2-carboxylic acid biphenyl-2-ylmethyl-pyridin-4-yl-amide;

N-Biphenyl-2-ylmethyl-*N*-(6-methoxy-pyridin-3-yl)-2-nitro-benzamide;

N-Biphenyl-2-ylmethyl-4-ethoxy-*N*-(6-methoxy-pyridin-3-yl)-benzamide;

5 *N*-Biphenyl-2-ylmethyl-2-ethoxy-*N*-pyridin-3-ylmethyl-benzamide;

Benzo[1,3]dioxole-4-carboxylic acid biphenyl-2-ylmethyl-pyridin-3-ylmethyl-amide;

10 *N*-Biphenyl-2-ylmethyl-2-bromo-*N*-pyridin-3-ylmethyl-benzamide;
and

 3-Chloro-*benzo*[b]thiophene-2-carboxylic acid biphenyl-2-ylmethyl-pyridin-3-ylmethyl-amide.

14. The compounds:

15 *N*-Biphenyl-2-ylmethyl-2-nitro-*N*-pyridin-3-ylmethyl-benzamide;

 2-Benzyl-*N*-biphenyl-2-ylmethyl-*N*-pyridin-3-ylmethyl-benzamide;

N-Biphenyl-2-ylmethyl-4-ethoxy-*N*-pyridin-3-ylmethyl-benzamide;

20 *N*-Biphenyl-2-ylmethyl-4-methoxy-*N*-(4-methoxy-phenyl)-benzamide;

N-Biphenyl-2-ylmethyl-2-ethoxy-*N*-(4-methoxy-phenyl)-benzamide;

Benzo[1,3]dioxole-5-carboxylic acid biphenyl-2-ylmethyl-(4-methoxy-phenyl)-amide;

25 *N*-Biphenyl-2-ylmethyl-2,4-dimethoxy-*N*-(4-methoxy-phenyl)-benzamide;

 2-Benzyl-*N*-biphenyl-2-ylmethyl-*N*-(4-methoxy-phenyl)-benzamide;

N-Biphenyl-2-ylmethyl-2-bromo-*N*-(4-methoxy-phenyl)-benzamide; and

Benzo[1,3]dioxole-4-carboxylic acid biphenyl-2-ylmethyl-(6-methoxy-pyridin-3-yl)-amide.

15. The compounds:

35 *N*-Biphenyl-2-ylmethyl-2-ethoxy-*N*-pyridin-2-yl-benzamide;

N-Biphenyl-2-ylmethyl-2-bromo-*N*-pyridin-2-yl-benzamide;

N-Biphenyl-2-ylmethyl-2-nitro-*N*-pyridin-2-yl-benzamide;

2-Benzyl-2-ylmethyl-N-pyridin-2-yl-benzamide;
N-Biphenyl-2-ylmethyl-2-bromo-*N*-pyridin-3-yl-benzamide;
3-Chloro-benzo[b]thiophene-2-carboxylic acid biphenyl-2-ylmethyl-pyridin-3-yl-amide;
5 Benzo[b]thiophene-2-carboxylic acid biphenyl-2-ylmethyl-pyridin-3-yl-amide;
N-Biphenyl-2-ylmethyl-2-nitro-*N*-pyridin-3-yl-benzamide;
N-Biphenyl-2-ylmethyl-2-ethoxy-*N*-pyridin-4-yl-benzamide; and
N-Biphenyl-2-ylmethyl-2-methoxy-*N*-pyridin-4-yl-benzamide.

10 16. The compounds:

Benzo[1,3]dioxole-4-carboxylic acid biphenyl-2-ylmethyl-pyridin-4-yl-amide;

N-Biphenyl-2-ylmethyl-2-bromo-*N*-pyridin-4-yl-benzamide;

N-Biphenyl-2-ylmethyl-2-nitro-*N*-pyridin-4-yl-benzamide;

15 2-Benzyl-2-ylmethyl-N-pyridin-4-yl-benzamide;

N-Biphenyl-2-ylmethyl-4-ethoxy-*N*-pyridin-4-yl-benzamide;

Benzo[b]thiophene-2-carboxylic acid biphenyl-2-ylmethyl-pyridin-3-ylmethyl-amide;

20 *N*-Biphenyl-2-ylmethyl-*N*-(4-methoxy-phenyl)-2-methylsulfanyl-benzamide;

N-Biphenyl-2-ylmethyl-2-isopropylsulfanyl-*N*-(4-methoxy-phenyl)-benzamide;

25 *N*-Biphenyl-2-ylmethyl-*N*-(3-methoxy-phenyl)-2-propylsulfanyl-benzamide; and

N-Biphenyl-2-ylmethyl-*N*-(3-methoxy-phenyl)-2-methylsulfanyl-benzamide.

17. The compounds:

30 *N*-Biphenyl-2-ylmethyl-2-isopropylsulfanyl-*N*-(3-methoxy-phenyl)-benzamide;

2-Benzylsulfanyl-*N*-biphenyl-2-ylmethyl-*N*-(3-methoxy-phenyl)-benzamide;

2-Benzylsulfanyl-*N*-biphenyl-2-ylmethyl-*N*-(4-chloro-phenyl)-benzamide;

35 *N*-Biphenyl-2-ylmethyl-*N*-(3,4-dimethoxy-phenyl)-2-propylsulfanyl-benzamide;

N-Biphenyl-2-ylmethyl-*N*-(3,4-dimethoxy-phenyl)-2-methylsulfanyl-benzamide;

N-Biphenyl-2-ylmethyl-*N*-(3,4-dimethoxy-phenyl)-2-isopropylsulfanyl-benzamide;

5 *N*-Biphenyl-2-ylmethyl-*N*-(3,4-dimethoxy-phenyl)-3-phenylsulfanyl-benzamide;

2-Benzylsulfanyl-*N*-biphenyl-2-ylmethyl-*N*-(3,4-dimethoxy-phenyl)-benzamide;

10 'N-Biphenyl-2-ylmethyl-*N*-(4-methoxy-phenyl)-2-(propane-1-sulfinyl)-benzamide; and

'N-Biphenyl-2-ylmethyl-*N*-(4-methoxy-phenyl)-2-(propane-2-sulfinyl)-benzamide.

18. The compounds:

15 '2-Benzenesulfinyl-*N*-biphenyl-2-ylmethyl-*N*-(4-chloro-phenyl)-benzamide;

'N-Biphenyl-2-ylmethyl-*N*-(3,4-dimethoxy-phenyl)-2-(propane-1-sulfinyl)-benzamide;

N-Biphenyl-2-ylmethyl-*N*-(3,4-dimethoxy-phenyl)-2-(propane-2-sulfinyl)-benzamide; and

20 *N*-Biphenyl-2-ylmethyl-*N*-(3,4-dimethoxy-phenyl)-2-phenylmethanesulfinyl-.

19. A pharmaceutical composition comprising a compound of Claim 1.

20. A pharmaceutical composition comprising a compound of Claim 7.

21. A method of treating atherosclerosis, the method comprising administering to a patient having or at risk of having atherosclerosis a therapeutically effective amount of a compound of Claim 1.

22. A method of treating atherosclerosis, the method comprising administering to a patient having or at risk of having atherosclerosis a therapeutically effective amount of a compound of Claim 7.

T E P A P P E L L A T U R E

23. A method of treating restenosis, the method comprising administering to a patient having or at risk of having restenosis a therapeutically effective amount of a compound of Claim 1.

24. A method of treating restenosis, the method comprising administering to a patient having or at risk of having restenosis a therapeutically effective amount of a compound of Claim 7.

5 25. A method of treating coronary heart disease, the method comprising administering to a patient having or at risk of having coronary heart disease a therapeutically effective amount of a compound of Claim 1.

10 26. A method of treating coronary heart disease, the method comprising administering to a patient having or at risk of having coronary heart disease a therapeutically effective amount of a compound of Claim 7.

27. A method of treating hyperlipidemia, the method comprising administering to a patient having hyperlipidemia a therapeutically effective amount of a compound of Claim 1.

15 28. A method of treating hyperlipidemia, the method comprising administering to a patient having hyperlipidemia a therapeutically effective amount of a compound of Claim 7.

29. A method of treating hyperlipoproteinemia, the method comprising administering to a patient having hyperlipoproteinemia a therapeutically effective amount of a compound of Claim 1.

20 30. A method of treating hyperlipoproteinemia, the method comprising administering to a patient having hyperlipoproteinemia a therapeutically effective amount of a compound of Claim 7.

31. A method of treating hypercholesterolemia, the method comprising administering to a patient having hypercholesterolemia a therapeutically effective amount of a compound of Claim 1.

32. A method of treating hypercholesterolemia, the method comprising 5 administering to a patient having hypercholesterolemia a therapeutically effective amount of a compound of Claim 7.

33. A method of treating hypertriglyceridemia, the method comprising administering to a patient having hypertriglyceridemia a therapeutically effective amount of a compound of Claim 1.

10 34. A method of treating hypertriglyceridemia, the method comprising administering to a patient having hypertriglyceridemia a therapeutically effective amount of a compound of Claim 7.

35. A method of treating obesity, the method comprising administering to an 15 obese patient a therapeutically effective amount of a compound of Claim 1.

36. A method of treating obesity, the method comprising administering to an obese patient a therapeutically effective amount of a compound of Claim 7.

20 37. A method of lowering plasma concentrations of apoB containing lipoproteins, the method comprising administering to a patient in need of lowering of apoB containing lipoproteins in plasma a therapeutically effective amount of a compound of Claim 1.

38. A method of lowering plasma concentrations of apoB containing 25 lipoproteins, the method comprising administering to a patient in need of lowering of apoB containing lipoproteins in plasma a therapeutically effective amount of a compound of Claim 7.

39. A method of lowering the plasma concentration of Lp(a), the method comprising administering to a patient in need of Lp(a) lowering a therapeutically effective amount of a compound of Claim 1.

40. A method of lowering the plasma concentration of Lp(a), the method comprising administering to a patient in need of Lp(a) lowering a therapeutically effective amount of a compound of Claim 7.

5 41. A method of lowering the plasma concentration of LDL, the method comprising administering to a patient in need of LDL lowering a therapeutically effective amount of a compound of Claim 1.

10 42. A method of lowering the plasma concentration of LDL, the method comprising administering to a patient in need of LDL lowering a therapeutically effective amount of a compound of Claim 7.

15 43. A method of lowering the plasma concentration of triglycerides, the method comprising administering to a patient in need of triglyceride lowering a therapeutically effective amount of a compound of Claim 1.

44. A method of lowering the plasma concentration of triglycerides, the method comprising administering to a patient in need of triglyceride lowering a therapeutically effective amount of a compound of Claim 7.